AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06168487
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be given telmisartan alone or with standard of care chemotherapy.
Trial: NCT06293638
Drug: Alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption is shown to reduce tremor in individuals with essential tremor. The alcoholic beverage will be dispensed by the a clinician study investigator, and the participant will be administered the alcoholic beverage until their tremor is decreased, as determined by the clinician. Individual sensitivity to the tremor-mitigating effects of alcohol varies, but it is anticipated that only light (1-2 40% ABV drinks, containing 1-2 units of absolute alcohol (10 mL. or 8 g of pure ethanol)) consumption will be necessary. Participants will then repeat motor task and data collection while the alcohol is effective at controlling tremor, beginning approximately 15-20 minutes after consumption.
Trial: NCT06293638
Drug: Alprazolam
RxNorm normalized name: Alprazolam
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam is shown to reduce tremor in individuals with essential tremor. The primary investigator will select the appropriate dose for the patient (0.5mg for patients with a body weight of up to 75kg, and 0.75mg for participants with a body weight of 75kg and higher). Participants will swallow the drug with a glass of water in the presence of the research team. If participants have not reached a sufficient level of tremor improvement, a subsequent dose of up to a total of 1.0mg of alprazolam per participant will be requested. Participants will then repeat motor task and data collection.
Trial: NCT06508606
Drug: AK117
RxNorm normalized name: Immunoglobulin g4 (225-proline), anti-(human cd47 antigen) (human-mus musculus monoclonal ak117 .gamma.4-chain), disulfide with human-mus musculus monoclonal ak117 .kappa.-chain, dimer
DrugBank: Ligufalimab (DB17542)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK117: 45mg/kg (D1, IVGTT, Q3W maintained for one year or until progression or intolerable toxicity occurred
Trial: NCT06508606
Drug: anti-EGFR
RxNorm normalized name: Anti-egfrviii/cd3 bite antibody amg 596
DrugBank: Etevritamab (DB17211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-EGFR:initial dose 400mg/m2, subsequent doses of 250mg/m2, D1, QW) maintained for one year or until progression or intolerable toxicity occurred
Trial: NCT04736953
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus
Trial: NCT00002440
Drug: Indinavir sulfate
RxNorm normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002440
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00002440
Drug: Abacavir sulfate
RxNorm normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002440
Drug: Amprenavir
RxNorm normalized name: Amprenavir
DrugBank: Amprenavir (DB00701)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00002440
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002440
Drug: Saquinavir
RxNorm normalized name: Saquinavir
DrugBank: Saquinavir (DB01232)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05858957
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: magnesium sulphate IV 30 mg/kg (10 min) infusion apply to the Group M
Trial: NCT05858957
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 ml saline infusion apply to the Group S
Trial: NCT06606067
Drug: Duloxetine
RxNorm normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 30 mg daily 2 weeks before surgery and 1 week after surgery
Trial: NCT06012279
Drug: Dapagliflozin 10mg Tab
RxNorm normalized name: DAPAGLIFLOZIN 10MG TAB
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin is a drug that works through inhibition of sodium glucose transporter-2 resulting in glucosuria.
Trial: NCT03276052
Drug: Aclidinium Bromide 400 μg
RxNorm normalized name: Aclidinium Bromide
DrugBank: Clidinium (DB00771)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
Trial: NCT05883332
Drug: Self-Administered Nitrous Oxide
RxNorm normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nitrous oxide administered at concentrations of mild sedation (20-50%)
Trial: NCT04763486
Drug: Cefazolin (Cefamezin)
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefamezin 2 gr within 6 hour of delivery
Trial: NCT05425654
Drug: Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
Trial: NCT05210868
Drug: CM355
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 1. Dose Escalation Phase CM355 will be taken by patients and will be treated follow the 3+3 dose escalation scheme~2. Expansion Phase CM355 will be taken by patients and will assess the efficacy of CM355 in patients with specific histopathological Non-Hodgkin's Lymphoma, and the safety of drug
Trial: NCT05728346
Drug: Allogeneic human pulp mesenchymal stem cells mixed with hyaluronic acid polymers
RxNorm normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: stem cells from human exfoliated deciduous teeth (SHED) mixed with hyaluronic acid polymers
Trial: NCT05011214
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients received 0.01 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.5% sevoflurane(FIO2=100%, 3L·min-1) was used to induce anaesthesia by mask inhalation and 3-4 % sevoflurane (adjusted according to the depth of the anaesthesia,FIO2=100%, 2L·min-1) was maintained
Trial: NCT05011214
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All patients received 0.1 mg/kg atropine and 1ug/kg dexmedetomidine iv as premedication.0.5mg·kg-1 esketamine was administered by vein in one minute, and 0.25mg·kg-1 esketamine was given at the beginning of the surgery.
Trial: NCT04851821
Drug: Quercetin
RxNorm normalized name: Quercetin
DrugBank: Quercetin (DB04216)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each patient included, after signing the consent, will have a treatment for ten days: one tablet times three per day 30 minutes before the meal.
Trial: NCT05753566
Drug: Rezvilutamide
RxNorm normalized name: Rezvilutamide
DrugBank: Rezvilutamide (DB19133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specifications of 80 mg; orally, once a day
Trial: NCT06430190
Drug: Peginterferon α-2b injection
RxNorm normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants receive CO2 laser treatment followed by local injection of 36mcg of Peginterferon α-2b directly into the base of each treated wart, repeated weekly for 12 weeks, and then followed for another 12 weeks.
Trial: NCT06430190
Drug: Peginterferon α-2b injection
RxNorm normalized name: peginterferon alfa-2b Injection
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants undergo CO2 laser treatment and then receive a weekly subcutaneous injection of 180mcg of Peginterferon α-2b for 12 weeks, and then followed for another 12 weeks.
Trial: NCT05529355
Drug: Envafolimab plus Endostar and S-1
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy combined with chemotherapy and anti VEGFR therapy
Trial: NCT05529355
Drug: Envafolimab plus Endostar
RxNorm normalized name: Envafolimab
DrugBank: Endostar (DB11727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy combined with anti VEGFR therapy
Trial: NCT05529355
Drug: Envafolimab plus S-1
DrugBank: Envafolimab (DB15769)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy combined with chemotherapy
Trial: NCT04557475
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Two tablets daily with dinner
Trial: NCT06507397
Drug: hyperbaric bupivacaine and fentanyl
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 3ml hyperbaric bupivacaine 0.5% combined with 25 microg of fentanyl.
Trial: NCT06507397
Drug: plain bupivacaine and fentanyl
RxNorm normalized name: bupivacaine and meloxicam
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients received 15 mL mixture of (0.25% plain bupivacaine and 50 µg fentanyl) over 5 minutes, injected in the epidural space by epidural catheter at L3-L4 interspace, a dural puncture was created by the spinal needle. Braun's Espocan® combined spinal epidural kit before insertion of epidural catheter (needle-through-needle technique) but intrathecal medication administration was withheld.
Trial: NCT04857437
Drug: PF-07202954 Repeat Dose
RxNorm normalized name: Tricontanyl Povidone (4 Tricontanyl Branches/Repeat)
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10, 30, 100, 300, 600, 1200 milligrams (mg)
Trial: NCT06258486
Drug: ICG injection
RxNorm normalized name: ICG-136
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient will have a green dye (ICG) injected into the lymph node to better visualize non-sealed leaks in order to pre-emptively seal any lymphatic leaks.
Trial: NCT05139381
Drug: Mepolizumab
RxNorm normalized name: Mepolizumab
DrugBank: Mepolizumab (DB06612)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment with Mepoluzimab
Trial: NCT04879849
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion.
Trial: NCT04879849
Drug: TAK-676
RxNorm normalized name: TAK-243
DrugBank: TAK-243 (DB15013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion.
Trial: NCT05043519
Drug: FAM-NP41
RxNorm normalized name: fam-trastuzumab deruxtecan-nxki
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients will be injected with FAM-NP41 in one dose intravenously 2 hours prior to the dural incision.
Trial: NCT05535738
Drug: Squaric Acid Dibutyl Ester
RxNorm normalized name: Squaric acid dibutyl ester
DrugBank: Squaric acid dibutyl ester (DB12223)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sensitization dose: 2% Elicitation doses: {0.0001%, 0.00025%, 0.00075%, 0.001%, 0.0025%, 0.005%, 0.0075%, 0.01%, 0.025%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6% 0.7%, 0.8%, 0.9%, 1.0%, 1.2%, 1.4%, 1.6%, 1.8%, 2.0%}
Trial: NCT05535738
Drug: Dupilumab
RxNorm normalized name: Dupilumab
DrugBank: Dupilumab (DB12159)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300mg
Trial: NCT05535738
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 40mg
Trial: NCT05535738
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 45mg
Trial: NCT05535738
Drug: Guselkumab
RxNorm normalized name: Guselkumab
DrugBank: Guselkumab (DB11834)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 100mg
Trial: NCT05535738
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 150mg
Trial: NCT05535738
Drug: Sarilumab
RxNorm normalized name: Sarilumab
DrugBank: Sarilumab (DB11767)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 200mg
Trial: NCT05535738
Drug: Triamcinolone Acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% ointment
Trial: NCT05535738
Drug: Betamethasone Valerate
RxNorm normalized name: Betamethasone Valerate
DrugBank: Betamethasone (DB00443)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.1% ointment
Trial: NCT05535738
Drug: Fluticasone Propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.005% ointment
Trial: NCT05320159
Drug: Secukinumab
RxNorm normalized name: Secukinumab
DrugBank: Secukinumab (DB09029)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Included all the patients treated with secukinumab
Trial: NCT04839471
Drug: BI-754091 plus afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eligible patients will receive BI-754091 240 mg on D1, afatinib 30 mg/day on day 1 to 21 in a 3-week cycle.
Trial: NCT04583254
Drug: Concurrent Chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly cisplatin 40 mg/m2 for a maximum of 5 cycles
Trial: NCT04909502
Drug: EHP-101 25 mg OD
RxNorm normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg OD during the first 28 Days of the trial
Trial: NCT04909502
Drug: EHP-101 25 mg BID
RxNorm normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg BID during the first 28 Days of the trial
Trial: NCT04909502
Drug: EHP-101 50 mg OD
RxNorm normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 28 Days of treatment with 25 mg OD, patients will escalate to 50 mg OD up to the end of the trial
Trial: NCT04909502
Drug: EHP-101 50 mg BID
RxNorm normalized name: EHP-102
DrugBank: EHP-102 (DB16933)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 28 Days of treatment with 25 mg BID, patients will escalate to 50 mg BID up to the end of the trial
Trial: NCT04287803
Drug: Methoxyflurane
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxyflurane 3mls will be self administered by patients meeting the inclusion criteria with acute traumatic pain scores \>=4
Trial: NCT04883528
Drug: Sacubitril / Valsartan Oral Tablet [Entresto]
RxNorm normalized name: sacubitril / valsartan Oral Tablet [Entresto]
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
Trial: NCT04831528
Drug: Cetuximab Ab; Bevacizumab; Vermofenib + cetuximab;Trastuzumab+lapatinib or trastuzumab+pertuzumab; others
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: After PD, patients received ctDNA testing, and different research protocols were selected according to different gene states of ctDNA, as follows: 1.No secondary changes related to drug resistance were found. Cetuximab cross-line + second-line chemotherapy (FOLFOX/FOLFIRI/ Irinotecan monotherapy, etc.) was used.2. If there is a RAS secondary mutation, change of beacizumab bead sheet resistance + second-line chemotherapy (FOLFOX/XELOX/stand for kang single-agent FOLFIRI mXEIRI/Iraq, etc.);3. If BRAF secondary mutation occurs, replace it with vimofenib + cetuximab + irinotecan;4. If HER2 amplification occurs, replace it with trastuzumab + lapatinib or trastuzumab + pertuzumab;5. In case of other secondary mutations, bevacizumab plus second-line chemotherapy should be replaced.
Trial: NCT06360081
Drug: Zongertinib
RxNorm normalized name: Zongertinib
DrugBank: Zongertinib (DB18762)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zongertinib
Trial: NCT00041171
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05981937
Drug: ICG solution
RxNorm normalized name: ICG-136
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICG-ATT is available at our institute since 2019 using a near-infrared (NIR) light source and special scope and camera equipped with xenon light (CARL STORZ GmbH \& Co. KG, Tuttlingen, Germany); ICG was supplied as a sterile water-soluble lyophilized powder (Diagnostic Green® GmbH). ICG-ATT is routinely used whenever available in daily practice with the following protocol: after the specimen resection the two colonic stumps or colonic and rectal stumps are checked with 5 cc of ICG 25 mg diluted in 10 cc of water sterile solution before fashioned anastomosis. Two laparoscopes with ICG-optic system are nowadays available department and ICG anastomosis control is always performed if ICG device are available (no performed in case of not available ICG instrument for sterilization in case of two consecutive surgery in the same day, concomitant ICG surgery or ICG malfunction).
Trial: NCT06508684
Drug: BTK inhibitor
RxNorm normalized name: BTK inhibitor CC-292
DrugBank: Spebrutinib (DB11764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTKi can refer to Orelabrutinib, Ibrutinib, Zanubrutinib, and Acalabrutinib
Trial: NCT05625373
Drug: Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The powder will be placed within the surgical wound prior to skin closure.
Trial: NCT05764668
Drug: Zihua Wenfei Zhisou Granule
RxNorm normalized name: camphor
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 14 daily- doses of Zihua Wenfei Zhisou Granule，one bag at a time (15 g/bag), three times/day
Trial: NCT04859244
Drug: GS-441524
RxNorm normalized name: GS-441524
DrugBank: GS-441524 (DB15686)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg administered as a solution
Trial: NCT05424263
Drug: Calcium Carbonate Oral Suspension
RxNorm normalized name: Calcium Carbonate Oral Suspension
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be supplemented with calcium carbonate (2,500 mg/day), as described in the arm/group descriptions, for 12 weeks.
Trial: NCT04104919
Drug: Brivoligide Injection 660 mg/6 mL
RxNorm normalized name: Brivoligide
DrugBank: Brivoligide (DB16116)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single preoperative intrathecal injection
Trial: NCT04962230
Drug: PF-07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: PF-07321332/ritonavir administered orally as a single dose on Day 1, Period 1
Trial: NCT04962230
Drug: Carbamazepine
RxNorm normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In Period 2, Days 1-3, participants will receive low-dose of carbamazepine twice daily (BID), then a titrated mid-dose of carbamazepine BID on Days 4-7, and finally maintaining carbamazepine at the high-dose on Days 8-15.
Trial: NCT04962230
Drug: PF 07321332/ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Period 2, Day 14, participants will receive a single dose of PF-07321332/ritonavir orally.
Trial: NCT05361499
Drug: Amoxicillin 500 mg
RxNorm normalized name: amoxicillin 500 MG
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin, 7 days, 2x 500 mg
Trial: NCT05551013
Drug: APG-157
RxNorm normalized name: APG-157
DrugBank: APG-157 (DB18683)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: APG-157 is an orally administered drug encased in a hydrogel pastille.~Arms:~* Ongoing Stupp protocol (will receive concurrent TMZ + APG-157)~* Progression post TMZ (will receive APG-157 only)~* Ongoing Optune (will receive concurrent Optune + APG-157)~* Progression post Optune (will receive APG-157 only)
Trial: NCT05962034
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 650 mg aspirin (Acetylsalicylic acid)
Trial: NCT05037487
Drug: Placebo Cannabis
RxNorm normalized name: Medical Cannabis
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked placebo cannabis
Trial: NCT05037487
Drug: 20 mg CBD Cannabis
RxNorm normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cannabis with CBD
Trial: NCT05037487
Drug: 20 mg CBD + 20 mg THC Cannabis
RxNorm normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cannabis with CBD and THC
Trial: NCT05037487
Drug: 20 mg THC Cannabis
RxNorm normalized name: Cannabis indica top
DrugBank: Medical Cannabis (DB14009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Smoked cannabis with THC
Trial: NCT05938920
Drug: INS018_055
RxNorm normalized name: INS018_055
DrugBank: INS018_055 (DB18083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical formulation: Capsules~Mode of Administration: Oral